I’m sure many readers will relate to Kylie’s observation that approval procedures can unintentionally iron out the novel ...

Asgard Therapeutics has appointed Prof Dr Wolfram Brugger as Chief Medical Officer, strengthening its leadership team as the ...

Novo Nordisk has presented new sub‑analyses from the phase 3 OASIS 4 trial at ECO2026, showing that oral semaglutide 25mg ...

The MHRA is establishing a new hub in Northern Ireland to support the region’s fast‑growing life sciences sector, in a move ...

Enterprise Therapeutics has reported that its phase 2 trial of ETD001, an investigational inhaled epithelial sodium channel ...

The Scottish medicines consortium has recommended the reimbursement of enfortumab vedotin with pembrolizumab for adults with ...

Poolbeg Pharma has received formal notification that its patent covering the use of p38 MAPK inhibitors, including POLB 001, for the prevention of cancer immunotherapy‑induced cytokine release ...

PulseSight Therapeutics has unveiled positive phase 1 results for PST‑611, its non‑viral gene therapy candidate for dry ...

Calla Lily Clinical Care has dosed the first patients in its Freedom clinical trial, a nihr‑funded study evaluating the ...

UCB has entered a new multi‑project strategic alliance with Cancer Research UK and its innovation arm, Cancer Research ...

Palisade Bio has released further phase 1a/b analyses of its investigational PDE4 inhibitor prodrug PALI‑2108, adding new ...

Omron has appointed Virendra Shelar as Executive Officer, President and CEO of Omron Europe. He will be based at the ...